Delivery Order SPE2DB25D3110-SPE2DB25FTEHM
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Otezla 30 mg tablets (60-count units) with a contract ceiling value of $29,588.62. This firm fixed-price delivery order, which is expected to conclude by August 15, 2025, represents a competitively awarded, non-set-aside contract with performance directed to AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award demonstrates the contractor's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Otezla 30 mg tablets (60-count units) at a firm fixed price with a ceiling value of $40,194.81 and an ultimate completion date of August 11, 2025. This non-set-aside, competitively awarded delivery order represents a continuation of AmerisourceBergen's ongoing support to federal medical procurement under its larger contract vehicle. The delivery is scheduled to take place...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Otezla 30 mg tablets (60-count units) with a ceiling value of $23,024.39. This firm fixed-price delivery order represents a non-set-aside award issued under competitive procurement and is scheduled for ultimate completion by August 22, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform all work at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Otezla 30 mg tablets (60-count units) under a firm fixed-price contract with a ceiling value of $9,345.06. This non-set-aside, competitively awarded delivery order is scheduled for completion by August 12, 2025, and represents a small-value pharmaceutical procurement supporting federal medical supply needs. The award is issued to AmerisourceBergen's corporate office, with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Otezla 30 mg tablets (60-count packaging) with a ceiling value of $27,320.78. This firm fixed-price delivery order, which is expected to be completed by July 24, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was made through open competition with no set-aside designation, reflecting...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Otezla 30 mg tablets (60-count units) with a ceiling value of $8,268.87. This competitively awarded, firm fixed-price delivery order is non-set-aside and reflects the contractor's ongoing role as a critical pharmaceutical vendor supporting federal medical procurement. The place of performance is located in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Otezla 30 mg tablets (60-count units) with a ceiling value of $33,943.97. This firm fixed-price delivery order represents a non-set-aside competitive award and is scheduled for ultimate completion by September 4, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $35,436.55 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on August 25, 2025, with an ultimate completion date of August 26, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The contract represents a single line item fulfilling pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $17,620.78 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, non-set-aside delivery order utilizes firm fixed pricing and represents a continuation of pharmaceutical supply services under AmerisourceBergen's broader federal contract portfolio. The product will be delivered to the company's corporate...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Otezla 30 mg tablets (60-count packages) valued at $31,870.76. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 19, 2025, with performance conducted at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. No set-aside designation was applied to this award, reflecting the company's...
- SPE2DB25D3110Indefinite Delivery Contract
- SPE2DB25D3110-SPE2DB25FTEHMDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Otezla 30 mg tablets (60-count packaging) with a ceiling value of $13,807.38. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award to this qualified pharmaceutical vendor. The order is scheduled for completion by September 9, 2025, and will be fulfilled from the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. This prime contract vehicle serves as a comprehensive global pharmaceutical support mechanism enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard. AmerisourceBergen's federal contract portfolio demonstrates consistent capability in delivering specialized medications across multiple therapeutic domains through competitively awarded delivery orders with firm fixed pricing.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.8k | 9/8/25 |